Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years

By Yahoo! Finance   |   1 month ago
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years

Roche's fenebrutinib shows promise in treating relapsing multiple sclerosis with no disability progression over 96 weeks. Promising results were presented at CMSC Annual Meeting, with ongoing Phase 3 trials. Roche's $50 billion U.S.

Read More

Did you find this insightful?